In a significant advancement for Alzheimer’s disease research, Anavex Life Sciences has reported promising results from its phase 2b/3 trial of blarcamesine (ANAVEX®2-73). The investigational therapy demonstrated a noteworthy reduction in amyloid-β biomarkers and a deceleration in brain atrophy among patients with early Alzheimer’s disease. These findings mark a crucial […]